SHIFTBIO’s pipeline is aiming to cure orphan diseases and cancer.
Candidate | SBI-101 [SIRP-Exo] |
Indication | Immunotherapy resistant solid tumor |
Rights |
Discovery | Pre-clinical |
Candidate | SBI-101 [SIRP-Exo] |
Indication | Immunotherapy resistant solid tumor |
Rights |
Discovery | Pre-clinical |
Candidate | SBI-101 [SIRP-Exo] |
Indication | Immunotherapy resistant solid tumor |
Rights |
Discovery | Pre-clinical |
Candidate | SBI-101 [SIRP-Exo] |
Indication | Immunotherapy resistant solid tumor |
Rights |
Discovery | Pre-clinical |
SHIFTBIO’s pipeline is aiming to cure orphan diseases and cancer.
Candidate | Indication | Development Phases | Rights | |
Discovery | Pre-clinical | |||
SBI-101 [SIRP-Exo] | Immunotherapy resistant | |||
SBI-102 [SIRP-Exo, MSC] | NASH with liver fibrosis | |||
SBI-103 [EGF-Exo] | Undisclosed | |||
SBI-104 [Apelin-Exo] | Pulmonary arterial hypertension | ![]() | ||
SBI-205 [Exo-HIF1α] | Liver damage | ![]() | ||
SBI-306 [RSFV-Exo-UP] | Immunotherapy resistant | |||
SBI-407 [Fc-Exo, MSC] | Undisclosed | |||
SBI-508 [Ag-Exo] | Immunotherapy resistant | |||
SBI-609, LGP-S01 [ImmuNano] | Undisclosed | ![]() |